Clinical Trial

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Name: A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation — clinical trial record (NCT06546280)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.

Trial Details

NCT Number	NCT06546280
Lead Sponsor	Zhujiang Hospital
Conditions	Hepatocellular Carcinoma
Enrollment	38 participants
Start Date	2024-08-26
Primary Completion	2026-08-26 (estimated)
Study Completion	2026-09-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-09